AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4827462 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/70 kg heroin
Number of subjects: 10
Study 4827462 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC procedures with hydrolysis
Number of subjects: 10
Study 4827462 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAT
Number of subjects: 10
Study 4827462 — intervention group
Group type: EXPERIMENTAL
Intervention: RIA
Number of subjects: 10
Study 4827462 — intervention group
Group type: COMPARATOR
Intervention: Technicon Autoanalyzer
Number of subjects: 10
Study 31620896 — intervention group
Group type: EXPERIMENTAL
Intervention: HPP/target therapy
Number of subjects: 62
Study 31620896 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy
Number of subjects: 62
Study 30839090 — intervention group
Group type: EXPERIMENTAL
Intervention: DWt + 400 mg/L of PLG
Number of subjects: 180
Study 30839090 — intervention group
Group type: EXPERIMENTAL
Intervention: DWt + 400 mg/L of LBS
Number of subjects: 180
Study 30839090 — intervention group
Group type: COMPARATOR
Intervention: DWt control (without MOO)
Number of subjects: 180
Study 27698102 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-start intervention group
Number of subjects: 80
Study 27698102 — intervention group
Group type: COMPARATOR
Intervention: Delayed-start intervention group (Control)
Number of subjects: 80
Study 24885592 — intervention group
Group type: EXPERIMENTAL
Intervention: Translation (TR) load
Number of subjects: 21
Study 24885592 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled tipping (CT) load
Number of subjects: 21
Study 23498096 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered tailored CRC screening intervention
Number of subjects: 693
Study 23498096 — intervention group
Group type: COMPARATOR
Intervention: Nontailored informational brochure about CRC screening
Number of subjects: 693
Study 21346110 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Fat Tolerance Test (OFTT: 1 g lipid/kg body weight) followed by caffeinated coffee (5 mg/kg)
Number of subjects: 10
Study 21346110 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (5 mg/kg)
Number of subjects: 10
Study 21346110 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee and decaffeinated coffee
Number of subjects: 10
Study 21346110 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 10
Study 21346110 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study 19233423 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride topical gel (1 gm, 10% weight per weight, ethanol based formulation) once daily for 12 weeks
Number of subjects: 789
Study 19233423 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 789
Study 16391591 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment (glucomannan and plant sterols)
Number of subjects: 34
Study 16391591 — intervention group
Group type: COMPARATOR
Intervention: Glucomannan
Number of subjects: 34
Study 12175635 — intervention group
Group type: EXPERIMENTAL
Intervention: C4AQ0 alleles observed in 45/73 (62%) NR
Number of subjects: 4269
Study 12175635 — intervention group
Group type: EXPERIMENTAL
Intervention: C4ADel observed in 24/73 (33%) NR
Number of subjects: 4269
Study 12175635 — intervention group
Group type: EXPERIMENTAL
Intervention: C4AQ0 alleles present in 21/49 (43%) NR without C4Del
Number of subjects: 4269
Study 10048740 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative enteral nutrition
Number of subjects: 60
Study 10048740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10048740 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nutritional status
Number of subjects: 60
Study 10048740 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative CMI score
Number of subjects: 60
Study 10048740 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in immunologic status from responding to anergy postoperatively
Number of subjects: 60
Study 7727966 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte‐depleted blood components (platelet concentrates and packed red cells)
Number of subjects: 52
Study 7727966 — intervention group
Group type: COMPARATOR
Intervention: Standard platelet concentrates and leukocyte‐depleted packed red cells (control group)
Number of subjects: 52
Study 1943932 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B1 and/or diuretics treatment for alcohol-related cardiomyopathy
Number of subjects: 1309
Study 7005293 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray (300 micrograms/day or less)
Number of subjects: 78
Study 7005293 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray
Number of subjects: 78
Study 7005293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 6432595 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-carotene/canthaxanthin
Number of subjects: 2
Study 6432595 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2
Study 29926675 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking group A (10,000-12,000 steps/day for 16 weeks)
Number of subjects: 80
Study 29926675 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking group B (10,000-12,000 steps/day for first 10 weeks, 14,000-15,000 steps/day for last 6 weeks)
Number of subjects: 80
Study 29926675 — intervention group
Group type: COMPARATOR
Intervention: Control group C (normal living conditions)
Number of subjects: 80
Study 26559156 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fruit and vegetable intake
Number of subjects: 0
Study 26559156 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fruit and vegetable intake among individuals with high processed meat intakes
Number of subjects: 0
Study 24774437 — intervention group
Group type: EXPERIMENTAL
Intervention: Posturographic platform biofeedback training (forced sway training) for 15 consecutive days
Number of subjects: 21
Study 24774437 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (control group)
Number of subjects: 21
Study 22894747 — intervention group
Group type: EXPERIMENTAL
Intervention: IT-based intervention (website and mobile phone)
Number of subjects: 317
Study 22894747 — intervention group
Group type: COMPARATOR
Intervention: Print-based intervention
Number of subjects: 317
Study 20211041 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose (iso; Palatinose)
Number of subjects: 0
Study 19023446 — intervention group
Group type: EXPERIMENTAL
Intervention: Librarian information (JIT service)
Number of subjects: 88
Study 19023446 — intervention group
Group type: COMPARATOR
Intervention: No librarian information (control group)
Number of subjects: 88
Study 16079422 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (educational pamphlet based on current evidence)
Number of subjects: 112
Study 16079422 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard nondirected discharge information sheet)
Number of subjects: 112
Study 11943797 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for abdominal aortic aneurysm
Number of subjects: 2342
Study 11943797 — intervention group
Group type: EXPERIMENTAL
Intervention: Active follow up every 3 months for men with an aortic diameter of 45-54 mm
Number of subjects: 2342
Study 10520573 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone patches (5 mg testosterone over 24 hours)
Number of subjects: 148
Study 10520573 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected men with weight loss (5 lb or more)
Number of subjects: 148
Study 10520573 — intervention group
Group type: COMPARATOR
Intervention: HIV-infected men without weight loss
Number of subjects: 148
Study 10520573 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected men
Number of subjects: 148
Study 10520573 — intervention group
Group type: COMPARATOR
Intervention: HIV-infected men with serum testosterone levels < 400 ng/dL
Number of subjects: 148
Study 7669218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-sucrose solution (1 mg/kg, 5 mg/kg, 10 mg/kg)
Number of subjects: 6
Study 7669218 — intervention group
Group type: COMPARATOR
Intervention: Sucrose solution (control)
Number of subjects: 6
Study 2187695 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss diet
Number of subjects: 0
Study 2187695 — intervention group
Group type: COMPARATOR
Intervention: Reduced sodium diet
Number of subjects: 0
Study 2187695 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss plus reduced sodium diet
Number of subjects: 0
Study 2187695 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced sodium plus increased potassium diet
Number of subjects: 0
Study 2187695 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 0
Study 7030902 — intervention group
Group type: EXPERIMENTAL
Intervention: Heptavax B vaccine (40 micrograms each, three doses)
Number of subjects: 1083
Study 7030902 — intervention group
Group type: EXPERIMENTAL
Intervention: Heptavax B vaccine
Number of subjects: 1083
Study 7030902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1083
Study 31495380 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency use (approximately 1 day/week)
Number of subjects: 720
Study 31495380 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence
Number of subjects: 720
Study 31495380 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent frequent use (approximately 4 days/week)
Number of subjects: 720
Study 29156875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.1 mg/kg IV 1 hour before anesthesia)
Number of subjects: 392
Study 29156875 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 392
Study 26529601 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g of calcium HMB for 8 weeks
Number of subjects: 80
Study 26529601 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HMB supplementation)
Number of subjects: 80
Study 23379828 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation with 2 cannulated compression screws combined with an iliac graft (n=44)
Number of subjects: 78
Study 23379828 — intervention group
Group type: COMPARATOR
Intervention: Internal fixation with 3 cannulated compression screws (n=34)
Number of subjects: 78
Study 21696115 — intervention group
Group type: EXPERIMENTAL
Intervention: Begg retainers
Number of subjects: 224
Study 21696115 — intervention group
Group type: EXPERIMENTAL
Intervention: Essix retainers
Number of subjects: 224
Study 21696115 — intervention group
Group type: COMPARATOR
Intervention: Both retainers
Number of subjects: 224
Study 19232793 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering diet
Number of subjects: 16
Study 19232793 — intervention group
Group type: COMPARATOR
Intervention: High glycemic index diet
Number of subjects: 16
Study 19232793 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Number of subjects: 16
Study 17360095 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 ('school') - medical students teaching BLS to school children
Number of subjects: 0
Study 17360095 — intervention group
Group type: COMPARATOR
Intervention: Group 2 ('EMS') - accompanied a BLS vehicle of the emergency medical service
Number of subjects: 0
Study 17360095 — intervention group
Group type: COMPARATOR
Intervention: Group 1 ('university') - attended a conventional university BLS/ALS course
Number of subjects: 0
Study 17360095 — intervention group
Group type: COMPARATOR
Intervention: Group 1 ('university')
Number of subjects: 0
Study 17360095 — intervention group
Group type: COMPARATOR
Intervention: Group 2 ('EMS')
Number of subjects: 0
Study 17360095 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 ('school')
Number of subjects: 0
Study 17360095 — intervention group
Group type: COMPARATOR
Intervention: Group 1 ('university') and Group 2 ('EMS')
Number of subjects: 0
Study 15145964 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort (300 mg tablet, three times daily for 14 days)
Number of subjects: 12
Study 15145964 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study 15145964 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort
Number of subjects: 12
Study 12528954 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond Fl (Kerr)
Number of subjects: 80
Study 12528954 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multipurpose (3M)
Number of subjects: 80
Study 12528954 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond Solo Plus (Kerr)
Number of subjects: 80
Study 12528954 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (3M)
Number of subjects: 80
Study 12528954 — intervention group
Group type: COMPARATOR
Intervention: Fourth-generation adhesive resin systems (filled and unfilled)
Number of subjects: 80
Study 12528954 — intervention group
Group type: COMPARATOR
Intervention: Fifth-generation adhesive resin systems (filled and unfilled)
Number of subjects: 80
Study 10430427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (0.75 mg, titrated to a maximum of 24 mg)
Number of subjects: 335
Study 10430427 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (1.25 mg, titrated to a maximum of 40 mg)
Number of subjects: 335
Study 10430427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 335
Study 10430427 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 335
Study 10430427 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 335
Study 10150437 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosurgery
Number of subjects: 208
Study 10150437 — intervention group
Group type: COMPARATOR
Intervention: CO2 laser ablation
Number of subjects: 208
Study 10150437 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosurgery and CO2 laser ablation
Number of subjects: 208
Study 1646621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg) and felodipine ER (10 mg)
Number of subjects: 12
Study 1646621 — intervention group
Group type: COMPARATOR
Intervention: Felodipine monotherapy
Number of subjects: 12
Study 1646621 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Ramipril and Felodipine)
Number of subjects: 12
Study 1646621 — intervention group
Group type: COMPARATOR
Intervention: Felodipine
Number of subjects: 12
Study 1646621 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 12
Study 6950685 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial irradiation plus 5 doses of i.t. MTX
Number of subjects: 61
Study 6950685 — intervention group
Group type: COMPARATOR
Intervention: One dose of i.t. MTX after induction, repeated every 3 months
Number of subjects: 61
Study 6950685 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG therapy by scarification
Number of subjects: 61
Study 6950685 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (initial relapses)
Number of subjects: 61
Study 6950685 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (mortality)
Number of subjects: 61
Study 6950685 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (survival rates)
Number of subjects: 61
Study 6950685 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (long-term remission)
Number of subjects: 61
Study 6950685 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (CNS relapses)
Number of subjects: 61
Study 6950685 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 61
Study 31999743 — intervention group
Group type: EXPERIMENTAL
Intervention: deprexis (tailored, integrative digital intervention)
Number of subjects: 2901
Study 29319497 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline plus high-dose cefoperazone-sulbactam (1:1)
Number of subjects: 42
Study 29319497 — intervention group
Group type: COMPARATOR
Intervention: Tigecycline monotherapy
Number of subjects: 42
Study 25101831 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (SIM) lipid-based formulation in gelatin capsules coated with Eudragit® S100
Number of subjects: 0
Study 25101831 — intervention group
Group type: COMPARATOR
Intervention: Zocor® tablets (reference control)
Number of subjects: 0
Study 25101831 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (SIM) lipid-based formulation
Number of subjects: 0
Study 24718367 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60-mg or 30-mg loading dose (LD)
Number of subjects: 0
Study 24718367 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600-mg loading dose (LD)
Number of subjects: 0
Study 22280120 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing facemasks and practicing intensified hand hygiene (MH group)
Number of subjects: 84
Study 22280120 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing facemasks only (M group)
Number of subjects: 84
Study 22280120 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 84
Study 20598667 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg intravitreal ranibizumab
Number of subjects: 184
Study 20598667 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg intravitreal ranibizumab
Number of subjects: 184
Study 20598667 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 184
Study 20598667 — intervention group
Group type: COMPARATOR
Intervention: Sham group patients who crossed over to 0.5 mg ranibizumab
Number of subjects: 184
Study 20598667 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab after rollover to monthly dosing
Number of subjects: 184
Study 20598667 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab after rollover to monthly dosing
Number of subjects: 184
Study 16767731 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-beta(2) enriched feeding
Number of subjects: 0
Study 16767731 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not enriched) feeding
Number of subjects: 0
Study 16368446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg QD AM
Number of subjects: 405
Study 16368446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg QD PM
Number of subjects: 405
Study 16368446 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 200 microg BID
Number of subjects: 405
Study 12196219 — intervention group
Group type: EXPERIMENTAL
Intervention: One-visit treatment with gutta-percha and AH-26 sealer
Number of subjects: 39
Study 12196219 — intervention group
Group type: COMPARATOR
Intervention: Two-visit treatment with calcium hydroxide for 4 weeks followed by gutta-percha and AH-26 sealer
Number of subjects: 39
Study 12196219 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive root-canal culture at the time of obturation
Number of subjects: 39
Study 12196219 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive bacterial culture (CFU<10(2)) at the time of filling
Number of subjects: 39
Study 9638715 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of mannitol
Number of subjects: 76
Study 9638715 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of mannitol
Number of subjects: 76
Study 9638715 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of mannitol
Number of subjects: 76
Study 9638715 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mannitol)
Number of subjects: 76
Study 7668437 — intervention group
Group type: EXPERIMENTAL
Intervention: Hotline fluid warmer
Number of subjects: 42
Study 7668437 — intervention group
Group type: COMPARATOR
Intervention: Control group without warner
Number of subjects: 42
Study 2574051 — intervention group
Group type: COMPARATOR
Intervention: SK&F 101468 (doses between 80 micrograms and 2.5 mg)
Number of subjects: 14
Study 2574051 — intervention group
Group type: COMPARATOR
Intervention: SK&F 101468 (up to 1 mg)
Number of subjects: 14
Study 2574051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31061252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography during hemodialysis sessions
Number of subjects: 7
Study 31061252 — intervention group
Group type: COMPARATOR
Intervention: X-ray before evaluation by US
Number of subjects: 7
Study 28363923 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based pulmonary rehabilitation
Number of subjects: 103
Study 28363923 — intervention group
Group type: COMPARATOR
Intervention: Conventional pulmonary rehabilitation
Number of subjects: 103
Study 26314532 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge bleeding (PDB)
Number of subjects: 8582
Study 26314532 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge myocardial infarction (PDMI)
Number of subjects: 8582
Study 23207247 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior 180-degree partial fundoplication
Number of subjects: 18
Study 23207247 — intervention group
Group type: COMPARATOR
Intervention: Nissen fundoplication
Number of subjects: 18
Study 21636245 — intervention group
Group type: EXPERIMENTAL
Intervention: High social anxiety individuals
Number of subjects: 170
Study 21636245 — intervention group
Group type: EXPERIMENTAL
Intervention: Low social anxiety individuals with low experiential avoidance (EA)
Number of subjects: 170
Study 19149939 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 12 IU/d
Number of subjects: 30
Study 19149939 — intervention group
Group type: COMPARATOR
Intervention: isotonic saline
Number of subjects: 30
Study 16522836 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 14656841 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin for seven days
Number of subjects: 156
Study 14656841 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin for three days followed by placebo for four days
Number of subjects: 156
Study 14656841 — intervention group
Group type: COMPARATOR
Intervention: Placebo for seven days
Number of subjects: 156
Study 14656841 — intervention group
Group type: COMPARATOR
Intervention: Penicillin (both regimens) vs Placebo
Number of subjects: 156
Study 14656841 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin treatment
Number of subjects: 156
Study 11138573 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 11
Study 11138573 — intervention group
Group type: COMPARATOR
Intervention: Relaxation condition
Number of subjects: 11
Study 9177418 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbimazole plus low dose CT (Calsynar; 100 IU/day, 2 days/week)
Number of subjects: 45